New Pharmaceutical Benefits Scheme listing for mental illness
People suffering schizophrenia and bipolar 1 disorder will have access to two drugs through the Pharmaceutical Benefits Scheme (PBS) from 1 February 2005.
View by date:Previous Ministers
30 November 2004
New Pharmaceutical Benefits Scheme listings for mental illnessPeople suffering schizophrenia and bipolar 1 disorder will have access to two drugs through the Pharmaceutical Benefits Scheme (PBS) from 1 February 2005.
Cabinet has approved the listing of Risperdal Consta®, a new injectable therapy for the treatment of schizophrenia, and of Zyprexa®, for the treatment of bipolar 1 disorder.
Approximately 60,000 people in Australia have schizophrenia and 100,000 have bipolar 1 disorder.
Risperdal Consta® is estimated to benefit around 10,000 patients who either cannot use existing subsidised treatments or have difficulty complying with their current treatment regime.
Bipolar 1 disorder is a serious illness characterised by severe ‘mood swings’ or episodes of mania and depression. Zyprexa® is effective to reduce the frequency and severity of manic episodes.
The annual cost to the PBS will be approximately $5,000 per patient for Risperdal Consta® and $2,000 per patient for Zyprexa®. Together, the listing of these drugs will add approximately $220 million to PBS expenditure by 2008/09.
For more information call Mr Abbott's office on ph 02 6277 7220.